Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in <scp>triple‐negative</scp>, <scp>early‐stage</scp> breast cancer (<scp>NeoCART</scp>): Results from a multicenter, randomized controlled, <scp>open‐label</scp> phase <scp>II</scp> trial

Abstract

Abstract Previous studies have shown that the addition of carboplatin to neoadjuvant chemotherapy improved the pathologic complete response (pCR) rate in patients suffering from triple‐negative breast cancer (TNBC) and patients who obtained a pCR could achieve prolonged event‐free survival (EFS) and overall survival (OS). However, no studies have assessed the effects of the combination of docetaxel and carboplatin without anthracycline with taxane‐based and anthracycline‐based regimens. The NeoCART study was designed as a multicenter, randomized controlled, open‐label, phase II trial to assess the efficacy and safety of docetaxel combined with carboplatin in untreated stage II‐III TNBC. All eligible patients were randomly assigned, at a 1:1 ratio, to an experimental docetaxel plus carboplatin (DCb) for six cycles group (DCb group) or an epirubicin plus cyclophosphamide for four cycles followed by docetaxel for four cycles group (EC‐D group). PCR (ypT0/is ypN0) was evaluated as the primary outcome. Between 1 September 2016 and 31 December 2019, 93 patients were randomly assigned and 88 patients were evaluated for the primary endpoint (44 patients in each group). In the primary endpoint analysis, 27 patients in the DCb group (61.4%, 95% CI 47.0‐75.8) and 17 patients in the EC‐D group achieved a pCR (38.6%, 95% CI 24.3‐53.0; odds ratio 2.52, 95% CI 2.4‐43.1; P noninferiority = .004). Noninferiority was met, and the DCb regimen was confirmed to be superior to the EC‐D regimen ( P = .044, superiority margin of 5%). At the end of the 37‐month median follow‐up period, OS and EFS rates were equivalent in both groups.